Five years experience on 3,4-diaminopyridine phosphate in Lambert–Eaton syndrome: Case reports

RATIONALE: To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert–Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids. PATIENT CONCERNS: Patients have...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Main Authors: Portaro, Simona, Brizzi, Teresa, Sinicropi, Stefano, Cacciola, Alberto, De Cola, Maria Cristina, Bramanti, Alessia, Milardi, Demetrio, Lupica, Antonino, Bramanti, Placido, Toscano, Antonio, Rodolico, Carmelo
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2017
Assuntos:
5300
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5617689/
https://ncbi.nlm.nih.gov/pubmed/28930822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000007839
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados